騰盛博藥－Ｂ (2137.HK)

9.160 +0.590 (+6.88%) 收市價： 04:08PM HKT

騰盛博藥－Ｂ

Building 7
3rd Floor, Zhongguancun Dongsheng Intl. S No. 1 North Yongtaizhuang Road Haidian Dist.
Beijing 100192
China

https://www.briibio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 113

高階主管

名稱	標題	支付	行使價	出生年份
Dr. Zhi Hong Ph.D.	Co-founder, Exec. Chairman & CEO	無	無	1964
Dr. Ankang Li C.F.A., J.D., Ph.D.	Chief Financial & Strategy Officer and Company Sec.	無	無	無
Ms. Karen Del Barrio Neuendorff	Chief People Officer & Head of HR	無	無	無
Mr. Yongqing Luo	Pres & GM of Greater China, CEO of TSB Therapeutics and Exec. Director	無	無	無
Mr. Coy Stout	Sr. VP, Head of U.S. Market Access & Patient Advocacy	無	無	無
Dr. Li Yan M.D., Ph.D.	Chief Medical Officer	無	無	無
Dr. Lianhong Xu Ph.D.	Sr. VP & Head of Medicinal Chemistry	無	無	無
Dr. Qing Zhu Ph.D.	Sr. VP & Head of Biopharmaceutical Research	無	無	無
Dr. David Margolis M.D., M.P.H.	VP & Head of Infectious Diseases Therapy Area	無	無	無

截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.

公司管治

截至 無 止，騰盛博藥－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。